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To explore the mechanisms underlying the eosinophil-mediated inflammation of tropical pulmonary eosin-
ophilia (TPE), bronchoalveolar lavage (BAL) fluid, serum, and supernatants from pulmonary and blood
leukocytes (WBC) from patients with acute TPE (n  6) were compared with those obtained from healthy
uninfected individuals (n  4) and from patients with asthma (n  4) or elephantiasis (n  5). Although there
were no significant differences in the levels of interleukin-4 (IL-4), IL-5, IL-13, eotaxin, granulocyte-macro-
phage colony-stimulating factor, RANTES, or eosinophil cationic protein, there was a marked increase in
eosinophil-derived neurotoxin (EDN) both systemically and in the lungs of individuals with TPE compared to
each of the control groups (P < 0.02). Moreover, there was a compartmentalization of this response, with EDN
levels being higher in the BAL fluid than in the serum (P < 0.02). Supernatants from WBC from either whole
blood or BAL cells were examined for chemokines, cytokines, eosinophil degranulation products, and arachi-
donic acid metabolites. Of the many mediators examined—particularly those associated with eosinophil
trafficking—only EDN (in BAL fluid and WBC) and MIP-1 (in WBC) levels were higher for TPE patients than
for the non-TPE control groups (P < 0.02). These data suggest it is the eosinophilic granular protein EDN, an
RNase capable of damaging the lung epithelium, that plays the most important role in the pathogenesis of TPE.
Tropical pulmonary eosinophilia (TPE), an unusual mani-
festation of human lymphatic filarial infection, is characterized
by an eosinophilic pulmonary inflammatory infiltrate and
marked elevations of immunoglobulin E (IgE) and circulating
eosinophils in the serum, all felt to be mediated by immuno-
logic hyperreactivity to filarial parasites or their antigens. Al-
though 129 million people worldwide are infected with lym-
phatic filariasis, 0.01% develop TPE (20). It is unclear what
factors predispose patients to the rare, localized, and profound
immune dysregulation associated with TPE.
Typically, microfilariae circulate in the blood of patients with
lymphatic filariasis without significant clinical consequences. In
the case of TPE, however, these microfilariae appear to be
trapped in the lung on their first pass through the circulation,
where they are presumed to initiate an inflammatory response.
The role of the filariae (and microfilariae, in particular) in the
immune response of TPE has been corroborated by lung bi-
opsy findings (37) and high levels of filaria-specific IgE and
IgG found in TPE patients (15, 24). In contrast to the majority
of people with lymphatic filariasis, who have a downregulated
response to the parasites (24), patients with TPE mount a
robust systemic and localized immune response that includes
elevations of both polyclonal and filaria-specific IgE and IgG
(23), as well as expansion of interleukin-4 (IL-4)- and IL-5-
producing T cells (19).
Compartmentalization of the immune response to the lungs
has been established by studies of bronchoalveolar lavage
(BAL) fluid from patients with TPE. The impressively high
levels of eosinophils found in the peripheral blood of TPE
patients (3,000/l) are surpassed in the lungs: levels have
been determined to be 12-fold more concentrated in the epi-
thelial lining fluid of the lungs than in the systemic circulation
(26). Eosinophils are the predominant effector cell in the BAL
fluid of patients with TPE, and unlike the rare eosinophils in
the BAL fluid of normal lungs, the pulmonary eosinophils in
TPE are degranulated and activated (26) and release abnor-
mally high levels of toxic oxygen radicals even after antifilarial
treatment (29). Filaria-specific IgE and IgG antibodies are
found in both the serum and BAL fluid of TPE patients;
however, the lung antibodies recognize a distinct subset of the
filarial antigens recognized by the antibodies in the periphery
(23), the most dominant being a parasite-derived -glutamyl
transpeptidase (16).
TPE has some parallels with atopic asthma, although bron-
chial hyperreactivity occurs much less frequently in TPE than
in asthma, and in TPE, the tissue and blood eosinophilia and
IgE elevations are more extreme (22). Although many media-
tors of eosinophilia (e.g., IL-5, granulocyte-macrophage colo-
ny-stimulating factor [GM-CSF], and IL-3 [7]), eosinophil traf-
ficking (RANTES, MIP-1 [3], and eotaxin [14]), and
eosinophil activation (LTB4 [21]) have been shown to be ex-
pressed at high levels in the BAL fluid of asthmatic patients
following allergen challenge, the mediators orchestrating eo-
sinophilic chemotaxis and activation in TPE are largely un-
known. The presence of eosinophilic granular proteins—eosin-
ophil-derived neurotoxin (EDN), MBP, and eosinophilic
cationic protein (ECP)—in the airways of patients with asthma
(2, 15) has led to the hypothesis that these proteins play a role
in the destruction of the bronchial epithelium (8); again, their
exact role in TPE remains unexplored.
A mild form of interstitial lung disease persists in the ma-
jority of patients treated for TPE (29). For the untreated TPE
patient, the outcome is more extreme: a progressive interstitial
fibrosis. In some diseases associated with intense tissue fibrosis,
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the abundance of degranulated eosinophils supports a link
between eosinophilic inflammation and fibrosis (6). Knowl-
edge of the early inflammatory mediators of TPE that could
potentiate tissue remodeling would further our understanding
of the chronic sequelae of TPE.
In this study, having access to cryopreserved BAL fluid and
serum material from TPE patients, we investigated many of the
cytokines, chemokines, eosinophilic granular proteins, and leu-
kotrienes that have been implicated in the pathology of other
eosinophil-mediated lung diseases to determine whether they
also play roles in TPE.
MATERIALS AND METHODS
Clinical study. In 1984, the Laboratory of Parasitic Diseases (National Insti-
tute of Allergy and Infectious Diseases, National Institutes of Health) and the
Pulmonary Branch (National Heart, Lung and Blood Institute, National Insti-
tutes of Health) jointly conducted a study in Madras, India, in which sera and
cell-free BAL fluid were collected from subjects who fulfilled the diagnostic
criteria for TPE and from three control groups (23, 26). The diagnosis of TPE
was based on the following criteria: residence in an area of endemicity in south-
ern India, recent onset of symptoms, chest X-ray infiltrates, restrictive defects in
lung function, peripheral eosinophilia, high total IgE in the serum, and high titers
of antifilarial IgG in the serum (25). Control group samples were obtained from
healthy uninfected and nonsmoking individuals (n  4), individuals with asthma
who had respiratory disease but no evidence of lymphatic filariasis (n  4), and
individuals with elephantiasis but without respiratory disease (n  5). The
healthy and elephantiasis control groups had normal chest X rays, chest exam-
inations, and pulmonary function tests. Patients with asthma had a history of
wheezing and exertional dyspnea and a clinical response to oral bronchodilators.
All of the asthma control group had normal pulmonary function tests at the time
of the study. The BAL procedure was performed using 300 ml of saline lavage
fluid as described previously (26).
Leukocytes (WBC) were obtained by dextran sedimentation of either whole
blood or BAL cells. After several washes in RPMI, the cells were cultured at a
concentration of 106/ml for 24 h in RPMI supplemented with HEPES (10 mM),
gentamicin (50 g/ml), and 10% fetal calf serum. After 24 h, the cell superna-
tants were collected and stored at 70°C until they were assayed. These samples
were available for a subgroup of the TPE and control patients.
ELISA and RNase assays. Stored and previously unthawed frozen BAL sam-
ples, sera, and cell-free WBC culture supernatants from the 1984 study were
examined by enzyme-linked immunosorbent assay (ELISA) analysis for chemo-
kine and cytokine production, eosinophil degranulation products, and arachi-
donic acid metabolites.
BAL values were normalized for volume to correct for the dilution of the
lavage fluid infused (27). Normalization based on comparing urea or albumin
concentrations in the periphery to the BAL fluid did not change the interpreta-
tion of the data (28).
Commercial ELISAs were used according to the manufacturer’s instructions
for IL-13, GM-CSF, IL-3 (Biosource International Inc.), MIP-1, LTB4, and
eotaxin (R&D Systems Inc.). IL-4, IL-5, and RANTES were measured using
antibody pairs and techniques described previously (32). EDN and ECP mea-
surements were performed as described previously (10), and the assay for BAL
RNase was performed exactly as described previously (12, 31).
Statistical analyses. Statistical analyses were performed using the Mann-
Whitney U test for comparisons of groups and the Wilcoxon signed rank test for
paired analyses. When multiple comparisons were made, Bonferroni’s correction
was applied.
RESULTS
Study population. The clinical data for the study and control
populations summarized in Table 1 represent a subset of pre-
viously reported individuals (23, 26, 29). As has been shown
previously, the serum IgE, eosinophilia, and serum antifilarial
IgG levels were significantly lower in the healthy, asthmatic,
and elephantiasis control groups than in those with TPE. All
individuals in the asthma control group had mild eosinophilia.
Only the TPE group had measurable antifilarial IgE levels in
the BAL fluid.
BAL and serum analysis. Despite the marked differences
in the serum IgE and peripheral eosinophil counts between
the subjects with TPE and the subjects in the three control
groups, there were no significant differences among the four
study groups in the levels of the eosinophilopoetic cytokines
(IL-5 and GM-CSF), the eosinophilic attractive chemokine
eotaxin, ECP, or the type 2 differentiating cytokines (IL-4 and
IL-13) in the serum (Table 2). Levels of RANTES, a known
eosinophil chemoattractant, in the sera of TPE patients were
significantly increased compared with those of either healthy
individuals or the non-TPE group as a whole (Table 2).
The cytokines (IL-4, IL-5, IL-13, and GM-CSF) and the
chemokines (eotaxin and RANTES) were below the level of
detection for all BAL samples (data not shown). The eosino-
philic granular protein ECP was detectable in all BAL samples,
but levels were not significantly different in the TPE group and
the other control groups (Table 2).
There was, however, a marked increase in EDN, both sys-
temically and in the lungs of individuals with TPE compared
with each of the other control groups (P  0.02) (Fig. 1). The
geometric mean (GM) levels of EDN for TPE patients (12,155
ng/ml) were on average 33-fold greater than for those with
asthma (358 ng/ml), 130-fold greater than for those with ele-
phantiasis (90 ng/ml), and 67-fold greater than for healthy in-
dividuals (181 ng/ml). Similarly, the GM of EDN in the sera of
TPE patients (706 ng/ml) was 7-fold greater than that of asth-
ma (85 ng/ml) or elephantiasis (90 ng/ml) patients and 32-fold
greater than that of healthy individuals (22 ng/ml). Indeed, the
TPE patient BAL fluid had RNase levels that were significantly
greater than those of normal control samples (P  0.05), and
there was a trend toward a positive relationship (P  0.06)
between the BAL EDN levels and the BAL RNase values.
Moreover, there was a compartmentalization of this re-
sponse, with EDN concentrations being higher in the BAL
fluid than in the serum when paired BAL fluid and serum EDN
levels were compared for each TPE patient (P  0.02) (Fig.
2A). For the elephantiasis group, the GMs of the BAL fluid
and serum EDN levels were very similar (89.9 ng/ml for BAL
TABLE 1. Clinical summary of study and control populations
Patient
group (n)
No. by
sexa
Age
(yr)
Peripheral
eosinophilia cells/l
of blood (range)
GM (103) BAL
eosinophilia cells/ml
(range [103])
GM serum IgE
(ng/ml) (range)
Range of serum
antifilarial IgG
(U/ml)
Range of BAL
antifilarial IgE
(ng/ml of ELFb)
TPE (6) 6/0 15–38 9,292 (6,286–41,210) 850 (304–2,490) 29,222 (6,286–53,333) 12,800–100,000 63.8–864
Normal (4) 3/1 18–26 511 (128–924) 19 (5–175) 2,769 (175–9,756) 200–1,600 0
Asthma (3) 3/0 19–31 1,073 (750–1,320) 1.4 (1–1.4) 524 (132–1,035) 100–800 0
Elephantiasis (5) 3/2 18–40 732 (444–903) 3.7 (2–8) 1,616 (358–1,563) 200–3,200 0
a Male/female.
b ELF, epithelial lining fluid.
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versus 90.2 ng/ml for serum EDN). In the ECP analysis, there
was a 10-fold difference between BAL fluid and serum ECP
levels for all TPE patients studied; however, this difference was
not statistically significant (Fig. 2B). There was no statistical
correlation between EDN levels and eosinophil levels in the
sera or BAL fluid of all groups (data not shown), suggesting
that the EDN levels were more reflective of eosinophil activa-
tion than of total numbers of eosinophils.
WBC and BAL fluid culture supernatant analysis. Because
a limited number of WBC and BAL fluid culture supernatants
were available for analysis, a preliminary analysis of material
from patients who had been recently treated for TPE was
performed for the many mediators associated with eosinophil
production, recruitment, and activation (including RANTES,
IL-13, GM-CSF, LTB4, MIP-1, IL-4, IL-5, eotaxin, ECP, and
EDN) (data not shown). After the analysis, we chose to look at
ECP, EDN, MIP-1, and LTB4. In this analysis, the asthma
and elephantiasis patients and healthy controls were pooled
into one group that was categorized as “non-TPE.”
Only EDN (in BAL fluid and WBC culture supernatants)
and MIP-1 (in WBC cultures) were significantly higher for
TPE patients than for the non-TPE control groups (P  0.02)
(Fig. 3). The contrast in EDN levels in the BAL fluid culture
supernatants between the TPE and non-TPE groups was strik-
ing (GM, 151 versus 2.5 ng/ml) (P  0.006); in the peripheral
FIG. 1. TPE is associated with increased levels of EDN in serum
(SER) (A) and in BAL fluid (B). Each individual’s value is represent-
ed by a circle. The top of the bar represents the GM for each group.
*, P  0.01; **, P  0.02. ELEPH, elephantiasis.
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blood white cell (PBWC) culture supernatants, the levels for
the TPE group were 2.7-fold higher than those for the non-
TPE group (GM, 121.4 versus 44.4 ng/ml). There was no sig-
nificant difference in ECP or LTB4 for the TPE group versus
the non-TPE group for the BAL fluid and PBWC culture su-
pernatant analyses. For MIP-1, there was a significant differ-
ence between the TPE and the non-TPE groups for the PBWC
culture supernatant analysis (GM, 251 versus 43.65 pg/ml; P 
0.02) but not for the BAL fluid culture supernatant analysis.
DISCUSSION
The purpose of this study was to uncover the cellular medi-
ators coordinating the eosinophil-rich inflammatory response
of acute TPE. Although an expansion of IL-4- and IL-5-pro-
ducing T cells may initiate and maintain the exuberant periph-
eral eosinophilia and IgE response seen systemically, this study
highlights the role of the activated and compartmentalized
eosinophil in the lungs of patients with TPE. It is also clear
from our study that the eosinophilic granular protein EDN, an
RNase capable of damaging the lung epithelium, plays a sig-
nificant role in the pathogenesis of TPE.
The findings of this study corroborate previous observations
that the immune response to Wuchereria bancrofti and Brugia
malayi is compartmentalized to the lungs in TPE (16, 23, 26).
Despite the massive eosinophilia in the lungs and systemically,
the significantly higher EDN levels in the BAL fluid (compared
with the serum) suggests that it is predominantly in the lungs
that the eosinophils are activated and degranulated in TPE. In
contrast, control patients with lymphatic filariasis (but without
lung disease) had nearly equivalent levels of EDN in the BAL
fluid and in the serum, as did those with asthma (lung disease
in the absence of peripheral eosinophilia). Significantly, the
high levels of EDN were not merely a reflection of the massive
eosinophilia in TPE: in our study, neither EDN nor ECP levels
were significantly related to the level of eosinophilia in the sera
or BAL fluid.
EDN levels in the sera of TPE patients were dramatically
higher than those in the sera of the comparable control group
who had lymphatic filariasis, suggesting that both antigenic
stimulation and eosinophil activation are present locally and
systemically in TPE patients. Compared with asthmatic pa-
tients, patients with TPE had remarkably higher levels of EDN
in the BAL fluid, presumably reflecting the intensity of the
eosinophilic response. Quiescent and active asthmatics typi-
cally manifest a mixed BAL cellular infiltrate of neutrophils
and lymphocytes and only a mild eosinophilia (17, 18), whereas
in TPE, the eosinophil is the predominant effector cell.
Interestingly, the concentration of EDN—but not of ECP—
was found to be significantly elevated in TPE patients for both
the serum and BAL samples compared to the three control
groups in our study. These data suggest that the release and
production of the granular proteins are regulated differently.
While it is unclear why EDN would have a special function in
TPE, there are studies suggesting that eosinophilic granular
proteins are under differential regulatory control, most notably
following treatment for filarial infection (10). EDN has also
been shown to have its own promoter, which is regulated by the
transcriptional factor C/EBP, indicating that there may be dif-
ferential transcriptional regulation of the eosinophil granule
proteins (ECPs) (5). Although it is not surprising that EDN, an
eosinophilic granular protein, is elevated in this disease char-
acterized by hypereosinophilia, it is perplexing that EDN, but
not ECP, was increased in the lungs and blood of TPE patients
in our study. Among the eosinophilic granular proteins, EDN
and ECP show the most similarities: both are cytotoxic and
helminthotoxic, and both belong to the same RNase A gene
superfamily (30).
Eosinophilic granular proteins are helminthotoxic in vitro
(11) and are elevated in filarial infections (33, 34). Filaricidal
activities, however, are not equivalent among the effector pro-
teins: per mole, ECP has greater in vitro microfilarial toxicity
against B. malayi than EDN (11), and MBP has been shown to
have the greatest helminthotoxic activity of the eosinophilic
granular proteins, due to its higher abundance in the granules
than the other granular proteins (1, 11). In one of the few
studies of filarial infections and eosinophilic granular proteins
published, both ECP and EDN levels in serum were found to
be significantly higher in patients with bancroftian filariasis and
onchocerciasis than in a control group from an area where the
diseases were not endemic and without filarial disease (33). In
our study, where the lymphatic filariasis control group was
much smaller, there was no such difference in the levels of
the eosinophilic granular proteins in the sera compared with
FIG. 2. EDN (A) and ECP (B) are compartmentalized to the lungs
of patients with TPE. Each line represents the levels of the eosino-
philic granule proteins for an individual patient with TPE. For the ECP
analysis, only four paired BAL and serum samples were available.
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a healthy control group; however, it is noteworthy that the
healthy control group in our study lived in an area where
filariasis is endemic.
In addition to different cytotoxic capabilities among the eo-
sinophilic proteins (1, 11), there is also evidence of different
host defense properties. Of the eosinophilic effector proteins,
MBP is unique in its ability to stimulate IL-8 release from
neutrophils in vitro (25). Although both EDN and ECP are
RNases, they may have unique effector functions. In vitro,
EDN alone has activity against respiratory syncytial virus (30).
ECP, but not EDN, can stimulate histamine release from rat
peritoneal mast cells (39). Surprisingly, the evolutionarily con-
served RNase activity shared by ECP and EDN (38) is not
responsible for the helminthotoxicity of ECP (11) or for the
antiviral activity of EDN (30).
Whether there is selective release of eosinophilic granular
proteins is controversial (13). Eosinophils require IgE or IgA
stimulation for the release of EDN in vitro, whereas IgA (but
not IgE) is necessary for the release of ECP (4, 35). Whether
this relationship is relevant in vivo is unproven, however. Fur-
thermore, in TPE, high levels of IgE in the serum suggest a
profound dysregulation of the typically well-regulated IgE re-
sponse (19). It is interesting to speculate whether the extreme
elevation of IgE in TPE has an impact on the specific release
of EDN.
There are many potential explanations as to why there was
not a significant increase in the other mediators measured. In
the cases of IL-5 and IL-13 in the serum and all the cytokines
and chemokines in the BAL fluid, the minimum levels of de-
tection for the assays were not sensitive enough to detect a
change. The majority of cytokines are produced locally, and
measurement of levels in a diluted BAL sample may not offer
enough sensitivity to detect subtle local increases. Instability of
the proteins after many years of storage may be another factor
affecting detection. MIP-1 was the only chemokine found to
be significantly elevated in TPE patients compared with con-
trols; however, this relationship was found only in the super-
natant of the PBWC culture and not in the supernatant of the
BAL fluid WBC culture. As chemokines are driven by concen-
tration gradients, it is likely that the increased MIP-1 is not
important in the pathogenesis of TPE.
The specific regulation of EDN and its role in TPE need to
be further elucidated. Notably, alpha interferon (IFN-) also
blocks the IgE-dependent release of EDN and the IgA-depen-
FIG. 3. EDN (A), ECP (B), MIP-1 (C), and LTB4 (D) levels in BAL fluid and PBWC culture supernatants in patients with (solid bars) and
without (hatched bars) TPE. Individual values are represented by circles. The top of the bar represents the GM for each group. The non-TPE group
is a pool of three healthy individuals, one elephantiasis patient, and one asthmatic patient. *, P  0.006; **, P  0.02. For the PBWC supernatant
analyses, the number of TPE samples was limited to four, as were the non-TPE samples.
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dent release of ECP in the activated eosinophil in vitro (4).
Clinically, IFN- has proven effective in the treatment of id-
iopathic hypereosinophilic syndrome (9). As EDN likely plays
a cytotoxic role in TPE, agents such as IFN- could be bene-
ficial in both the acute and chronic phases of the disease.
The currently available treatment with diethylcarbamazine,
while effective in ameliorating the acute symptoms, leaves a
majority of patients with subtle lung abnormalities long after
treatment (29). In a certain number of patients (12 to 25%)
(36), the dose of diethylcarbamazine is inadequate for cure,
leaving the patients vulnerable to relapses and to chronic fi-
brosis. Priority should be given to the development of com-
bined antifilarial and anti-inflammatory treatment strategies
that target the acute eosinophil-mediated syndrome of TPE
and prevent the serious fibrotic sequelae seen in the disease.
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